课题基金 / 基金详情

ISLET TRANSPLANTATION IN KIDNEY TRANSPLANT RECIPIENTS W/TYPE 1 DIABETES

ISLET TRANSPLANTATION IN KIDNEY TRANSPLANT RECIPIENTS W/TYPE 1 DIABETES
1 型糖尿病肾移植受者的胰岛移植
批准号:
7377843
负责人:
ALEXANDER C WISEMAN
金额:
$0.22万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2007-03-31

项目摘要

项目成果

ALEXANDER C WISEMAN的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。本申请的目的是利用GCRC资源移植人类胰岛(胰岛素产生细胞),用于治疗因糖尿病肾病而患有肾衰竭并曾接受过肾移植的1型糖尿病患者。从20世纪70年代初到2000年,近400例1型糖尿病患者接受了胰岛移植,但在“埃德蒙顿经验”之前,该队列中只有41例患者在移植后实现了胰岛素独立。胰岛移植作为一种治疗1型糖尿病的方法,在埃德蒙顿的阿尔伯塔大学取得了巨大的成功,自2000年以来,世界各地的其他多个中心也报道了这一成功。该组显示,在两个供体胰腺的顺序胰岛移植和随后使用白细胞介素-2受体抗体daclizumab、西罗莫司和低剂量他克莫司进行免疫抑制后,1型糖尿病的持续逆转。埃德蒙顿方案的成功激发了美国国立卫生研究院资助的临床试验的创建(免疫耐受网络胰岛移植试验在全球范围内招募了10个中心,以模仿阿尔伯塔大学的方法)和由美国国立卫生研究院(NCRR)资助的“胰岛细胞资源中心”(ICRs)的发展,以优化每个胰腺的潜在移植使用。我们的中心,科罗拉多大学健康科学中心,被选为参与胰岛细胞资源中心的10个中心之一。目前,我们的实验室已获得美国国立卫生研究院(NIH)批准,根据cGMP指南进行胰岛细胞分离,并在36个月内进行了64次胰岛分离手术。我们已经启动了一项临床试验,以模仿埃德蒙顿方案作为评估胰岛移植功能和结果的标准(GCRC #1391),现在计划扩大研究对象人群,包括已经使用免疫抑制药物来维持先前肾移植的受试者。本研究的目的是在单中心试点研究中评估胰岛异体移植对1型糖尿病患者重建稳定血糖控制和稳定肾移植功能的安全性和有效性。胰岛异体移植的潜在候选者将包括年龄大于或等于18岁的1型糖尿病患者,具有稳定的肾移植功能,并且正在服用与上述胰岛移植试验相同的药物。不良事件将在移植后的头两年进行监测和记录。将评估移植后3个月及以后具有完全(胰岛素独立性和HbA1c<7%)和部分(胰岛素依赖性,基础或刺激c肽水平大于或等于0.5ng/mL,糖化血红蛋白小于或等于7%)胰岛移植功能的1型糖尿病异体胰岛移植受体的比例。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this application is to utilize GCRC resources to transplant human pancreatic islets (insulin-producing cells) for the treatment of type 1 diabetes in patients who have kidney failure and have previously received a kidney transplant as a result of diabetic kidney disease. Islet transplants have been performed in nearly 400 patients with type1 diabetes from the early 1970's to 2000, but prior to the "Edmonton experience", only forty-one recipients of this cohort had achieved insulin independence following transplantation. Islet transplantation as a treatment for type1 diabetes has dramatically improved with successes reported at the University of Alberta in Edmonton followed by multiple other centers around the world since the year 2000. This group demonstrated consistent reversal of Type1 diabetes following sequential islet transplantation from two donor pancreases and subsequent immunosuppression with the interlukin-2 receptor antibody daclizumab, sirolimus, and low-dose tacrolimus. The success of the Edmonton Protocol has provoked the creation of an NIH-funded clinical trial (the Immune Tolerance Network Islet Transplant Trial enlisting 10 centers worldwide to emulate the methodology of the U of Alberta) and the development of "Islet Cell Resource Centers" (ICRs) funded by the NIH (NCRR) to optimize the use of each pancreas for potential transplant. Our center, the University of Colorado Health Sciences Center, was one of 10 centers selected for participation as an Islet Cell Resource Center. At present, our laboratory has gained NIH approval for islet cell isolation under cGMP guidelines and has performed 64 pancreatic islet isolation procedures over 36 months. We have initiated a clinical trial to emulate the Edmonton protocol as a standard from which to assess function and outcomes of islet transplantation (GCRC #1391) and now plan to expand the study subject population to include subjects who are already on immunosuppressive medications to sustain a previous kidney transplant. The objective of this study is to assess the safety and efficacy of islet allotransplantation for the re-establishment of stable blood sugar control in patients with type 1 diabetes and stable kidney transplant function in a single-center pilot study. Potential candidates for islet allotransplantation will include patients greater than or equal to 18 years of age with type 1 diabetes, who have had stable kidney transplant function, and who are on medications identical to the above-mentioned islet transplant trials. Adverse events will be monitored and recorded throughout the first two years post-transplant. The proportion of type 1 diabetic islet allograft recipients with full (insulin independence and HbA1c<7%) and partial (insulin dependence, basal or stimulated C-peptide levels of greater or equal to 0.5ng/mL and glycated hemoglobin less than or equal to 7%) islet graft function at 3 months post transplant and beyond will be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISLET TRANSPLANTATION IN KIDNEY TRANSPLANT RECIPIENTS W/TYPE 1 DIABETES
  • 批准号:
    7719479
  • 项目类别:
  • 资助金额:
    $0.06万
  • 财政年份:
    2008
  • 负责人:
    ALEXANDER C WISEMAN
  • 依托单位:
ISLET TRANSPLANTATION FOR TYPE 1 DIABETES
  • 批准号:
    7719449
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2008
  • 负责人:
    ALEXANDER C WISEMAN
  • 依托单位:
ISLET TRANSPLANTATION IN KIDNEY TRANSPLANT RECIPIENTS W/TYPE 1 DIABETES
  • 批准号:
    7604429
  • 项目类别:
  • 资助金额:
    $0.54万
  • 财政年份:
    2007
  • 负责人:
    ALEXANDER C WISEMAN
  • 依托单位:
ISLET TRANSPLANTATION FOR TYPE 1 DIABETES
  • 批准号:
    7604399
  • 项目类别:
  • 资助金额:
    $0.94万
  • 财政年份:
    2007
  • 负责人:
    ALEXANDER C WISEMAN
  • 依托单位:
海外基金